are expected to make biosimilars affordable to more people and drive the growth of the global biosimilar market . Nonoriginal biologics and bio betters provide major challenge to the biosimilar market . Non-original biologics are duplicate products of reference biologics found in markets with lesser regulations or relaxed intellectual property protection . Though bio betters are regulated , as stepwise upgrade of innovator molecules , they are finding space in the drugs market . The lack of clear guidelines for the interchangeability or substitution of drugs with bio-similar is a restraint for the growth of the biosimilar market . The high manufacturing cost and complexity of production , along with the unclear regulatory policies in many countries are expected to be the major restraints for the global biosimilar market during the forecast period . However , due to the lower prices of biosimilars , the treatment for many diseases such as diabetes , rheumatoid arthritis and types of cancers , are anticipated to become affordable in developing countries and it provide opportunities for major players in the global biosimilar market to expand during the forecast period . Moreover , strategic partnerships between biosimilar manufacturers , manufacturing of multiple biosimilar products in same production facility and outsourcing of manufacturing to third parties are expected to help the major players to expand faster during the forecast period .
Segments Covered :
The report segments the global biosimilar market by product , application and region . On the basis of product , the market is segmented as human growth hormones , monoclonal antibodies , insulin , peptides , erythropoietin and others . Based on application , the market is segmented as oncology , chronic and autoimmune diseases , growth hormone deficiency , infectious diseases and others .
Geographic Coverage and Analysis :
The report provides regional analysis covering geographies such as North America , Europe , Asia-Pacific , and Rest of the World . With the maximum number of approved biosimilars , European market is the major biosimilar market in the world . Countries such as France , Germany , Italy and United Kingdom drive the growth of the European biosimilar market with high demand for low cost alternatives for biologics medicines . Expiry of patents for certain biologics medicines and presence of good regulatory frameworks set up by European Medical Association are expected to aid the growth of the European biosimilar market , during the forecast period . Asia-Pacific region has significant biosimilars in use due to the relaxed regulations in various countries . Due to the presence of large population and need for low cost alternative medicines for
Infinium Global Research